GLA Antikörper
Kurzübersicht für GLA Antikörper (ABIN7114447)
Target
Alle GLA Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Aufreinigung
- Immunogen affinity purified
-
Reinheit
- ≥95 % as determined by SDS-PAGE
-
Immunogen
- galactosidase, alpha
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- WB: 1:500-1:5000, IHC: 1:20-1:200, IP: 1:500-1:5000
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Buffer
- PBS with 0.02 % sodium azide and 50 % glycerol pH 7.3,
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- -20°C for 12 months (Avoid repeated freeze / thaw cycles.)
-
Haltbarkeit
- 12 months
-
-
- GLA (Galactosidase, alpha (GLA))
-
Andere Bezeichnung
- Alpha galactosidase A
-
Hintergrund
- Synonyms:Alpha galactosidase A, galactosidase, alpha Background:GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.
-
Molekulargewicht
- 49 kDa
-
Gen-ID
- 2717
-
UniProt
- P06280
-
Pathways
- SARS-CoV-2 Protein Interaktom
Target
-